gambierol: structure in first source
ID Source | ID |
---|---|
PubMed CID | 6442244 |
CHEMBL ID | 266438 |
MeSH ID | M0400087 |
Synonym |
---|
CHEMBL266438 |
(-)-gambierol |
unii-844q8wc5f6 |
844q8wc5f6 , |
gambierol |
146763-62-4 |
(1s,3r,5s,7r,10s,11r,13s,15r,17s,20r,22s,24r,26s,27s,29s,31r,33s,35r)-11-[(1z,3z)-hepta-1,3,6-trienyl]-29-(3-hydroxypropyl)-3,5,10,24,26-pentamethyl-2,6,12,16,21,25,30,34-octaoxaoctacyclo[18.16.0.03,17.05,15.07,13.022,35.024,33.026,31]hexatriacont-8-ene-1 |
DTXSID30880110 |
Gambierol is a marine polycyclic ether toxin produced by the marine dinoflagellate Gambierdiscus toxicus and is a member of the ciguatoxin toxin family. It primarily targets voltage-gated potassium channels (K(v) channels) in excitable membranes.
Gambierol has been associated with neurological symptoms in humans. Its mechanism of action has not been fully characterized.
Excerpt | Reference | Relevance |
---|---|---|
"Gambierol has been demonstrated to be either a low-efficacy partial agonist/antagonist of voltage-gated sodium channels or a potent blocker of voltage-gated potassium channels (Kvs)." | ( Gambierol inhibition of voltage-gated potassium channels augments spontaneous Ca2+ oscillations in cerebrocortical neurons. Busse, E; Cao, Z; Cui, Y; Mehrotra, S; Murray, TF; Rainier, JD, 2014) | 2.57 |
"Gambierol has been associated with neurological symptoms in humans even though its mechanism of action has not been fully characterized." | ( The sodium channel of human excitable cells is a target for gambierol. Botana, LM; Cagide, E; Fuwa, H; Louzao, MC; Sasaki, M; Vieytes, MR; Yasumoto, T, 2006) | 1.3 |
Excerpt | Reference | Relevance |
---|---|---|
" In many cases, the lack of toxic material turns out to be an obstacle to make the toxicological investigations needed." | ( Comparative cytotoxicity of gambierol versus other marine neurotoxins. Ares, IR; Botana, LM; Cagide, E; Espiña, B; Fuwa, H; Konno, Y; Louzao, MC; Paquette, LA; Sasaki, M; Tsukano, C; Vieytes, MR; Yasumoto, T; Yotsu-Yamashita, M, 2011) | 0.66 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID212037 | Minimal lethal dose of compound expressed as toxicity against male mice (ddY strain) after intraperitoneal administration | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Synthesis and biological evaluation of gambierol analogues. |
AID1177025 | Induction of leak current in wild-type CHO cells by electrophysiology method | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 | Evaluation of gambierol and its analogs for their inhibition of human Kv1.2 and cytotoxicity. |
AID1177027 | Cytotoxicity against CHO cells transfected with human Kv 1.2 assessed as growth inhibition after 72 hrs by WST-8 assay | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 | Evaluation of gambierol and its analogs for their inhibition of human Kv1.2 and cytotoxicity. |
AID1177024 | Inhibition of human Kv 1.2 stably expressed in CHO cells by whole cell patch clamp method | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 | Evaluation of gambierol and its analogs for their inhibition of human Kv1.2 and cytotoxicity. |
AID1177026 | Cytotoxicity against wild-type CHO cells assessed as growth inhibition after 72 hrs by WST-8 assay | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 | Evaluation of gambierol and its analogs for their inhibition of human Kv1.2 and cytotoxicity. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 29 (65.91) | 29.6817 |
2010's | 14 (31.82) | 24.3611 |
2020's | 1 (2.27) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.84) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 4 (9.09%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 40 (90.91%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |